Menu
← Oncology Approval Tracker
FDA DECISION ·
Yescarta
axicabtagene ciloleucel · Kite Pharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with large B-cell lymphoma refractory to first-line chemoimmunotherapy or relapsing within 12 months after it.
LAMPGEN ANALYSIS
Why it matters
The action moves CAR T-cell therapy earlier for patients with primary refractory disease or early relapse.
What research teams should watch
Calculate the first-line-to-relapse interval and coordinate referral before subsequent treatment changes cell collection or timing.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
CAR T-cell studies in relapsed or refractory DLBCLPRIMARY RECORDS